Literature DB >> 3441162

The bioavailability of Tamoplex (tamoxifen). Part 2. A single dose cross-over study in healthy male volunteers.

P J Guelen1, D Stevenson, R J Briggs, D de Vos.   

Abstract

Tamoxifen and N-desmethyltamoxifen plasma concentrations were determined in a single dose cross-over study with Tamoplex and Nolvadex at the dose height of 40 mg in 18 healthy male volunteers with a wash-out period of at least 140 days. ANOVA, power analysis and novel bioequivalence tests on AUC, Cmax and tcmax, including a non-parametric one, demonstrated bioequivalence of Tamoplex and Nolvadex 10 mg tablets. The mean AUC ( +/- SD) values of tamoxifen after administration of Tamoplex or Nolvadex tablets were 1076 +/- 265 and 1131 +/- 301 h ng ml-1, respectively. ANOVA on the AUC values gave a p value of 0.450 with a power of 0.85 and a 95% confidence interval of 81.8-108.5% was obtained. The 0.8 power test showed a determined difference of 18.9%, whereas the actual difference was 4.9%. Interindividual and intraindividual variation was assessed. The pharmacokinetic data, well established for 34 hr, constitute a basis for further studies on tamoxifen distribution, elimination and metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3441162

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  5 in total

1.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  The bioavailability of three altretamine formulations.

Authors:  E A Runhaar; J P Neijt; J J Holthuis; D de Vos
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

3.  The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients.

Authors:  P H Slee; D De Vos; D Chapman; D Stevenson
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

Review 5.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.